-
Prof. Zefei Jiang Previews Highlights and Reflects on a Decade of Growth in Chinese Oncology
2025 BOC/BOA to Open on July 4th! From BOA to BOC/BOA: Chinese Scholars on the Global Stage Oncology Frontier: BOC/BOA 2025 is just around the corner. Over the years, you’ve…
-
Prof. Jun Guo Invites Global Oncologists to Witness “China’s Rise” and Share the Latest from ASCO
See You in Nanjing for BOC/BOA 2025! Rooted in China, Looking to the World BOC/BOA Celebrates the Rise of Chinese Oncology Oncology Frontier: Could you share the vision behind organizing…
-
YBCSG 2025 Mid-Year Meeting | Prof. Hengyu Li: Advancing Liver Metastasis Management and Multidisciplinary Collaboration to Bring Hope to Breast Cancer Patients
The “YBCSG 2025 Mid-Year Breast Cancer Collaboration Meeting and Post-ASCO Symposium,” held recently in Shanghai, gathered experts to discuss clinical updates in breast cancer treatment. At the event, Prof. Hengyu Li—Secretary General of the Yangtze River Breast Cancer Study Group (YBCSG) and a leading expert at Shanghai Changhai Hospital, Naval Medical University—delivered a comprehensive presentation…
-
BOC/BOA 2025 Preview | Prof. Jinming Yu: A Decade of Progress Elevates China’s Fight Against Cancer—Uniting Global Wisdom for a New Journey Ahead
The 2025 Annual Conference of the Chinese Society of Clinical Oncology (BOC) and Best of ASCO® 2025 China (BOC/BOA) will be held on July 4–5 in Nanjing. This year’s event coincides with the 10th anniversary of the China Clinical Oncology Annual Research Progress publication—marking a key milestone in China’s oncology journey. Over the past decade,…
-
YBCSG 2025 Mid-Year Meeting | Prof. Leiping Wang: Latest Advances in HER2-Positive Breast Cancer at ASCO 2025 and Reflections on Clinical Practice
At the recent “Yangtze Breast Cancer Collaboration Mid-Year Meeting and the Mid-Year Meeting of the Oncology Drug Clinical Research Committee of the Chinese Medical Education Association,” Professor Leiping Wang from Fudan University Shanghai Cancer Center delivered a keynote presentation titled “New Advances in HER2-Positive Breast Cancer at ASCO 2025 and My Clinical Practice.” Oncology Frontier…
-
Professor Ting Li on TROP2-Targeted ADC Advances in TNBC at ASCO 2025 and Practical Insights for Young Investigators Conducting IIT Studies
Oncology Frontier invited Professor Li for an in-depth interview to discuss major research updates on TROP2 ADCs in the treatment of mTNBC presented at ASCO 2025 and their clinical implications,…
-
Xinghai Roundtable | ADCs Redefine First-Line Treatment in HER2+ mBC: Expert Insights on Sequencing, Strategy, and Retreatment Approaches
DB-09 Redefines the First-Line Standard in Advanced Disease Oncology Frontier: The DB-09 study presented at ASCO 2025 has drawn significant attention and set a new benchmark for median PFS in…
-
Xinghai Roundtable | Spotlight on ASCO 2025: Advancing Precision Treatment Strategies for Early-Stage TNBC
Oncology Frontier: In the context of adjuvant therapy for early-stage TNBC, the Fudan Oncology team previously demonstrated the value of adding carboplatin in the PATTERN study (PCb vs. CEF-T). However,…
Connecting Medical Expertise through Media